Medicus Pharma Soars 13.17% on Acquisition News

Medicus Pharma's stock surged 13.17% in pre-market trading on May 13, 2025, reflecting significant investor optimism and market confidence in the company's recent strategic moves.

D. Boral Capital has raised its price target for Medicus Pharma from $14 to $27, maintaining a Buy rating. This adjustment comes after Medicus Pharma announced its acquisition of Antev through a binding letter of intent. The acquisition is expected to introduce Teverelix, an advanced GnRH antagonist, into Medicus' portfolio. Teverelix has strong clinical support and is nearing market readiness, targeting two significant medical markets: preventing recurrence of acute urinary retention and treating advanced prostate cancer in patients at high cardiovascular risk.

Analysts view this acquisition as a strategic pipeline expansion that mitigates risk and enhances Medicus Pharma's near-commercial offerings. The move is seen as a step towards increased value creation in the near future, further bolstering investor confidence in the company's growth prospects.